+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Nanomedicine Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797899
The global nanomedicine market size attained a value of USD 239.1 billion in 2022. The market is anticipated to grow at a CAGR of 12.2% during the forecast period of 2023-2031 to attain a value of USD 677.7 billion by 2031.

Nanomedicine Market: Introduction

Nanomedicine refers to the application of nanotechnology in the field of healthcare and medicine. It involves the design, development, and utilization of nanoscale materials and devices (typically with dimensions less than 100 nanometres) for diagnosis, treatment, monitoring, and prevention of diseases. Nanomedicines can include a wide range of materials such as nanoparticles, nanodevices, and even molecular machines that can interact with biological systems at the molecular level.

Uses of nanomedicines:
  • Drug delivery: Nanomedicines can be used for targeted drug delivery, improving the efficiency and specificity of drugs while reducing side effects. Nanoparticles can be engineered to carry and release drugs at specific sites in the body, minimizing the exposure of healthy tissues to the drugs and enhancing their therapeutic effects
  • Diagnostics: Nanoscale devices and materials can be used for early and accurate diagnosis of diseases. For example, nano sensors and quantum dots can be used to detect biomarkers, while gold nanoparticles can be employed for enhanced imaging techniques
  • Regenerative medicine: Nanomedicines can aid in tissue engineering and regenerative medicine by providing scaffolds for cell growth, delivering growth factors, and enabling controlled release of bioactive molecules
  • Theranostics: Nanomedicines can serve as theranostic agents, which combine diagnostic and therapeutic functions in a single platform, enabling personalized medicine and real-time monitoring of treatment responses
Benefits of nanomedicines:
  • Improved efficacy: Nanomedicines can improve the efficacy of drugs by enhancing their solubility, stability, and bioavailability, as well as enabling targeted delivery and controlled release
  • Reduced side effects: By targeting drugs specifically to diseased cells or tissues, nanomedicines can minimize the exposure of healthy cells to the drugs, thereby reducing side effects and improving patient compliance
  • Early detection and treatment: Nanoscale diagnostic tools enable early detection of diseases, allowing for timely intervention and improved treatment outcomes
  • Personalized medicine: Nanomedicines can be tailored to individual patients' needs, offering customized therapies based on specific genetic, molecular, or cellular characteristics
  • Reduced healthcare costs: By improving the efficiency and effectiveness of treatments, nanomedicines have the potential to reduce overall healthcare costs
In summary, nanomedicines represent a promising frontier in healthcare, with the potential to revolutionize diagnostics, drug delivery, and personalized medicine. These advances may lead to more effective treatments, fewer side effects, and ultimately, better patient outcomes.

Nanomedicine Market Segmentations

The market can be categorised into product type, type, modality, indications, and regions.

Market Breakup by Product Type

  • Therapeutics
  • Regenerative Medicine
  • Vaccines
  • Others

Market Breakup by Type

  • Nanoparticles
  • Gold Nanoparticles
  • Iron Oxide Nanoparticles
  • Hydrogel Nanoparticles
  • Others
  • Nano shells
  • Nano Devices
  • Others

Market Breakup by Modality

  • Diagnostic
  • Treatment

Market Breakup by Indications

  • Drug Delivery
  • Diagnostic Imaging
  • Tissue Regeneration
  • Infectious Disease
  • Orthopaedics
  • Neurological disease
  • Oncology
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Nanomedicine Market Scenario

The global nanomedicine treatment market has been experiencing significant growth in recent years, driven by advancements in nanotechnology, increased investment in research and development, and a growing demand for personalized and targeted therapies. This market scenario encompasses various aspects, including industry trends, key players, and regional analysis, which contribute to the overall landscape.

Industry trends:
  • Increased focus on targeted drug delivery: As the understanding of diseases at the molecular level improves, the demand for targeted drug delivery systems has risen. This has led to the development of various nanocarriers, such as liposomes, dendrimers, and polymeric nanoparticles, which can enhance the efficacy and reduce the side effects of drugs
  • Growing interest in theranostics: The concept of theranostics, which combines diagnostics and therapeutics in a single platform, has gained significant attention. This approach enables personalized medicine and real-time monitoring of treatment responses, leading to better patient outcomes
  • Technological advancements: Innovations in nanotechnology have facilitated the development of novel nanomaterials and devices with improved properties and functionalities. These advancements are expected to drive the growth of the nanomedicine treatment market

Key Players in the Global Nanomedicine Market

The report gives an in-depth analysis of the key players involved in the nanomedicine market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Abbott
  • Invitae Corporation
  • General Electric Company
  • Leadiant Biosciences, Inc
  • Johnson & Johnson Services, Inc
  • Mallinckrodt
  • Merck Sharp & Dohme Corp
  • Nanosphere Health Sciences, Inc
  • Pfizer Inc
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd
  • Gilead Sciences, Inc
  • Amgen Inc
  • Bristol-Myers Squibb Company
  • Abbvie Inc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Lilly
  • Nanobiotix
  • Sanofi

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Nanomedicine Market Overview
3.1 Global Nanomedicine Market Historical Value (2016-2022)
3.2 Global Nanomedicine Market Forecast Value (2023-2031)
4 Global Nanomedicine Market Landscape
4.1 Global Nanomedicine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Nanomedicine Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Modality
4.2.3 Analysis by Indications
5 Global Nanomedicine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Nanomedicine Market Segmentation
6.1 Global Nanomedicine Market by Product Type
6.1.1 Market Overview
6.1.2 Therapeutics
6.1.3 Regenerative Medicine
6.1.4 Vaccines
6.1.5 Others
6.2 Global Nanomedicine Market by Type
6.2.1 Market Overview
6.2.2 Nanoparticles Gold Nanoparticles Iron Oxide Nanoparticles Hydrogel Nanoparticles Others
6.2.3 Nano shells
6.2.4 Nano Devices
6.2.5 Others
6.3 Global Nanomedicine Market by Modality
6.3.1 Market Overview
6.3.2 Diagnostic
6.3.3 Treatment
6.4 Global Nanomedicine Market by Indications
6.4.1 Market Overview
6.4.2 Drug Delivery
6.4.3 Diagnostic Imaging
6.4.4 Tissue Regeneration
6.4.5 Infectious Disease
6.4.6 Orthopedics
6.4.7 Neurological disease
6.4.8 Oncology
6.4.9 Others
6.5 Global Nanomedicine s Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Nanomedicine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Nanomedicine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Nanomedicine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Nanomedicine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Nanomedicine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 Abbott
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Invitae Corporation
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 General Electric Company
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Leadiant Biosciences, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Johnson & Johnson Services, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mallinckrodt
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Merck Sharp & Dohme Corp.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Nanosphere Health Sciences, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Celgene Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Gilead Sciences, Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Amgen Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Bristol-Myers Squibb Company
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Abbvie Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Novartis AG
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 F. Hoffmann-La Roche Ltd
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Luminex Corporation
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Lilly
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Nanobiotix
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
17.21 Sanofi
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
17.21.5 Certifications
18 Global Nanomedicine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Abbott
  • Invitae Corporation
  • General Electric Company
  • Leadiant Biosciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt
  • Merck Sharp & Dohme Corp.
  • Nanosphere Health Sciences, Inc.
  • Pfizer Inc.
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Lilly
  • Nanobiotix
  • Sanofi



Table Information